The Biologics Price Competition and Innovation Act (BPCIA) of 2010 initially posed significant barriers to biosimilar ...
On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which ...
A retrospective study of a mandatory nonmedical switch in Canada found no significant differences in rates of treatment persistence, loss of response, or adverse events in patients with inflammatory ...
The FDA approved a new strength of a trastuzumab biosimilar; UnitedHealth will remove reference adalimumab from some ...
Number 3: Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is ...
In September 2024, the FDA approved a new biosimilar for treating retinal conditions, marking a significant development in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback